Myeloma and second primary cancers

New England Journal of Medicine

Volumn 365, Issue 23, 2011, Pages 2241-2242

  Landgren, Ola ^a   Thomas, Anish ^a   Mailankody, Sham ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LENALIDOMIDE; MELPHALAN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANTIBODY BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; DNA POLYMORPHISM; DRUG MEGADOSE; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; LOW DRUG DOSE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND CANCER;

EID: 83155182810     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1111010     Document Type: Letter

References (5)

1. Turesson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2010;28:830-4.
2. Swerdlow AJ, Barber JA, Hudson GV, et al. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000;18:498-509. (Pubitemid 30078531)
3. Mailankody S, Pfeiffer RM, Kristinsson SY, et al. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011;118:4086-92.
4. Landgren O, Ma W, Kyle RA, Rajkumar SV, Korde N, Albitar M. Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myeloma. Leukemia 2011 September 16 (Epub ahead of print).
5. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005;5:943-55. (Pubitemid 41781694)